SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending intensely following the FDA approval of YARTEMLEA, its first and only therapy for transplant-associated thrombotic microangiopathy (TA-TMA), a critical condition with no prior approved treatments. The community is buzzing with speculation about the stock's significant undervaluation, potential for a short squeeze, and the possibility of a buyout from Novo Nordisk, building on their existing multi-billion dollar licensing deal.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu (SHIB) is trending with highly polarized community sentiment as investors debate its immediate future. Many loyal holders view recent price action as a prime accumulation opportunity, anticipating a strong rally, while a vocal contingent labels it a "scam" or "shitcoin" and questions its underlying value. This prominent meme coin continues to generate significant conversation regarding its potential amidst broader market volatility.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending sharply higher following the announcement of its acquisition by Sanofi, significantly boosting Sanofi's adult immunization portfolio with Heplisav-B and a promising shingles vaccine candidate. While many long-term investors express disappointment over the agreed price, viewing it as an undervaluation, others are relieved to see an exit after years of holding amid prior discussions about management's performance and shareholder value.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is drawing significant attention after its depression drug failed a Phase 2 study and its SCA treatment received an FDA Complete Response Letter, leading to a company restructuring. Despite these setbacks, substantial insider buying and an intense community focus on highly anticipated data from its epilepsy, obesity, and oncology programs are driving conversations about potential future value. Investors are actively discussing whether the current valuation presents a strategic entry point for its diverse pipeline.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is a trending topic after reporting robust earnings, showcasing a critical milestone with its first positive adjusted EBITDA, coupled with increased revenue guidance that signals continued growth in AI-driven precision medicine. Despite these strong results and several analyst upgrades, the community is actively debating recent price volatility, with many expressing long-term conviction in the company's AI-driven healthcare platform while others point to "sell the news" dynamics and market manipulation.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is gaining attention for its central role in Co-Packaged Optics (CPO) and Silicon Photonics, supplying crucial components for TSMC's COUPE platform, which is integral to advanced AI chips from major players like NVIDIA and AMD. The community is highly engaged, discussing the immense future revenue potential from this technology and emerging AR/AI applications, though some express impatience regarding the timeline for these innovations to significantly impact the company's financial results.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

Opgen (OPGN OTC) is trending due to its strategic pivot towards an AI-driven fintech platform, CapForce, which is generating significant community discussion around a potential Nasdaq relisting. Investors are closely watching recent SEC filings and the substantial insider ownership from AEI Capital, fueling speculation of a major valuation increase for this low-float stock focused on Asian digital investment banking.

Willow Lane Acquisition Corp. is a blank check company, which engages for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 3, 2024 and is headquartered in New York, NY.

Willow Lane Acquisition Corp. - Ordinary Shares - Class A

Willow Lane Acquisition Corp. (WLAC) is currently trending due to its pending merger with Boost Run LLC, an AI cloud infrastructure provider that specializes in bare-metal GPU computing for enterprise and government clients. The community is actively discussing its potential as a severely undervalued opportunity in the high-demand AI sector, frequently comparing it to successful peers like NBIS and CRWV. Anticipation is building for significant upside as the merger progresses, fueled by Boost Run's projected strong growth and profitability.

Spire Global, Inc. collects space-based data using a proprietary constellation of low earth multi-use receiver nanosatellites. Its software analytics generate proprietary data, insights and predictive analytics for its customers through a subscription model. The company was founded by Peter Platzer in August 2012 and is headquartered in Vienna, VA.

Spire Global Inc - Ordinary Shares - Class A

Spire Global is trending following recent significant contract awards, including a large defense program with a substantial ceiling and an expanded IoT agreement, alongside its strategic partnership with NVIDIA for AI-powered weather models. The company recently strengthened its financial position by completing the sale of its maritime business, becoming debt-free with a boosted cash reserve. Despite these positive developments and multiple analyst upgrades, community discussions reflect ongoing frustration over past financial reporting delays and perceived market undervaluation.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is trending as community discussions compare its interoperability vision and performance against emerging rivals like Keeta, which champions superior throughput and compliance-first architecture for institutional financial flows. Many investors express frustration over ATOM's prolonged price declines, which often overshadow its high staking rewards, amidst ongoing community efforts to redesign its tokenomics for long-term sustainability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UBS has adjusted their stance on Halliburton ( $HAL ), setting the rating to Neutral with a target price of 24 → 32.